Min Min Yang
Chief Executive Officer chez PHARMABLOCK SCIENCES (NANJING), INC.
Fortune : 226 M $ au 31/03/2024
Profil
Fondateur de PharmaBlock Sciences (Nanjing), Inc, Min Min Yang est président de cette société. Il siège également au conseil d'administration de Shanghai Ark Biopharmaceutical Co, Ltd.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/07/2023 | 30 980 300 ( 99,23% ) | 169 M $ | 31/03/2024 | |
| 03/07/2023 | 10 326 800 ( 6,13% ) | 56 M $ | 31/03/2024 |
Postes actifs de Min Min Yang
| Sociétés | Poste | Début |
|---|---|---|
| PHARMABLOCK SCIENCES (NANJING), INC. | Chief Executive Officer | 21/04/2023 |
| GEMPHARMATECH CO., LTD. | Director/Board Member | 19/10/2023 |
Shanghai Ark Biopharmaceutical Co., Ltd.
 Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Director/Board Member | 01/03/2021 |
Formation de Min Min Yang
| Auburn University | Doctorate Degree |
| Nanjing University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PHARMABLOCK SCIENCES (NANJING), INC. | Commercial Services |
| GEMPHARMATECH CO., LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Health Technology |
